報價延遲最少15分鐘:2025/05/14 00:52 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.2 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.74/-1.98
|
|
企業價值
95.85M
|
| 資產負債 |
|
每股賬面淨值
3.57
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/14 00:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing apipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. |